Spruce Biosciences Inc (NASDAQ: SPRB) on Tuesday, plunged -3.41% from the previous trading day, before settling in for the closing price of $0.41. Within the past 52 weeks, SPRB’s price has moved between $0.34 and $5.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 24.68%. With a float of $28.56 million, this company’s outstanding shares have now reached $41.30 million.
Let’s determine the extent of company efficiency that accounts for 29 employees. In terms of profitability, gross margin is -14.36%, operating margin of -608.94%, and the pretax margin is -555.23%.
Spruce Biosciences Inc (SPRB) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Spruce Biosciences Inc is 30.86%, while institutional ownership is 23.54%. The most recent insider transaction that took place on Mar 21 ’24, was worth 350,951. In this transaction 10% Owner of this company sold 465,021 shares at a rate of $0.75, taking the stock ownership to the 2,550,000 shares. Before that another transaction happened on Mar 18 ’24, when Company’s 10% Owner sold 842,020 for $0.77, making the entire transaction worth $647,008. This insider now owns 3,968,000 shares in total.
Spruce Biosciences Inc (SPRB) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.77% during the next five years compared to -22.95% drop over the previous five years of trading.
Spruce Biosciences Inc (NASDAQ: SPRB) Trading Performance Indicators
Spruce Biosciences Inc (SPRB) is currently performing well based on its current performance indicators. A quick ratio of 5.36 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of Spruce Biosciences Inc (SPRB)
Looking closely at Spruce Biosciences Inc (NASDAQ: SPRB), its last 5-days average volume was 0.58 million, which is a jump from its year-to-date volume of 0.48 million. As of the previous 9 days, the stock’s Stochastic %D was 49.62%. Additionally, its Average True Range was 0.03.
During the past 100 days, Spruce Biosciences Inc’s (SPRB) raw stochastic average was set at 21.36%, which indicates a significant decrease from 37.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.09% in the past 14 days, which was lower than the 65.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3949, while its 200-day Moving Average is $0.5075. However, in the short run, Spruce Biosciences Inc’s stock first resistance to watch stands at $0.4145. Second resistance stands at $0.4302. The third major resistance level sits at $0.4403. If the price goes on to break the first support level at $0.3887, it is likely to go to the next support level at $0.3786. Should the price break the second support level, the third support level stands at $0.3629.
Spruce Biosciences Inc (NASDAQ: SPRB) Key Stats
Market capitalization of the company is 16.48 million based on 41,303K outstanding shares. Right now, sales total 10,090 K and income totals -47,920 K. The company made 600 K in profit during its latest quarter, and -8,670 K in sales during its previous quarter.
